-
Halozyme Therapeutics (HALO) PT Raised to $47 at BMO Capital, Following Business Update And Guidance
-
Halozyme Therapeutics (HALO) PT Raised to $25 at BMO Capital, Following FY 2020 Guidance
-
UPDATE: BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform
-
Halozyme Therapeutics (HALO) PT Lowered to $16 at BMO Capital
-
Halozyme Therapeutics (HALO) PT Lowered to $17 at BMO Capital
-
Halozyme Therapeutics (HALO) PT Lowered to $19 at BMO Capital
-
Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital
-
Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital
-
Halozyme Therapeutics (HALO) PT Raised to $19 at BMO Capital
-
Weakness Expected in Halozyme Therapeutics (HALO) as SWOG mFFOX Combo Too Toxic for PEGPH20 Benefit - BMO
-
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
-
BMO Capital Starts Halozyme Therapeutics (HALO) at Market Perform
-
Notable Analyst Rating Changes 2/1: (JOY) (PFPT) (VRTX) Upgraded; (ARR) (GPC) (AIG) Downgraded
-
Halozyme Therapeutics (HALO) Bullish Stance Reiterated at BMO Capital Amid Positive AACR Update
-
Halozyme Therapeutics (HALO) PT Raised to $26 at BMO Capital
-
Halozyme Therapeutics (HALO) Surges Following Impressive Data for PEGPH20 in Pancreatic Cancer from Investor Day
-
Halozyme Therapeutics (HALO) Q1 Report 'Solid' on Multiple Fronts - BMO Capital
-
BMO Capital Defends Halozyme Therapeutics (HALO); Buy on Weakness
-
Halozyme Therapeutics (HALO) Prices 7.7M Offering at $13/Share
-
Pre-Open Stock Movers 9/3: (NOK) (HALO) (TU) Higher; (CYTK) (STP) (MSFT) Lower (more...)
-
Unusual 11 Mid-Day Movers 01/14: (AZK) (HALO) (CXPO) Higher; (TELK) (BIOL) (NTE) Lower
-
StreetInsider.com Pre-Open Movers 01/14: (VRNT) (FRAN) (RIG) Higher; (NTE) (AAPL) (CRUS) Lower (more...)
-
BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform
-
BMO Cuts Halozyme (HALO) to Market Perform Following FDA's Request for More Info on HyQ Application
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform